Chimerix Inc
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases in the United States. Its product pipeline comprising dordaviprone (ONC201), which is in phase 3 clinical-stage development for H3 K27M-mutant diffuse glioma, as well as in phase 2 Investigator Initiated Clinical Trials for multiple oncology studies; and ONC206, a sec… Read more
Chimerix Inc (CMRX) - Total Liabilities
Latest total liabilities as of March 2025: $24.33 Million USD
Based on the latest financial reports, Chimerix Inc (CMRX) has total liabilities worth $24.33 Million USD as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Chimerix Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how Chimerix Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Chimerix Inc Competitors by Total Liabilities
The table below lists competitors of Chimerix Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SANGETSU CO LTD
OTCGREY:SGSUF
|
USA | $70.08 Billion |
|
CrossFirst Bankshares Inc
NASDAQ:CFB
|
USA | $6.81 Billion |
|
Robinsons Retail Holdings Inc
PINK:RRETY
|
USA | $89.47 Billion |
|
Surgery Partners Inc
NASDAQ:SGRY
|
USA | $4.39 Billion |
|
Quanex Building Products
NYSE:NX
|
USA | $1.25 Billion |
|
Concentric AB (publ)
PINK:CCNTF
|
USA | $2.00 Billion |
|
Scholastic Corporation
NASDAQ:SCHL
|
USA | $-264.70 Million |
|
COMSTOCK HLDG-A
F:CHO
|
Germany | €1.08 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Chimerix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chimerix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chimerix Inc (2011–2024)
The table below shows the annual total liabilities of Chimerix Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $24.33 Million | +23.22% |
| 2023-12-31 | $19.75 Million | -12.18% |
| 2022-12-31 | $22.48 Million | -30.36% |
| 2021-12-31 | $32.29 Million | +184.55% |
| 2020-12-31 | $11.35 Million | +20.41% |
| 2019-12-31 | $9.42 Million | -28.12% |
| 2018-12-31 | $13.11 Million | -2.31% |
| 2017-12-31 | $13.42 Million | +27.25% |
| 2016-12-31 | $10.55 Million | -48.64% |
| 2015-12-31 | $20.53 Million | +19.09% |
| 2014-12-31 | $17.24 Million | +16.12% |
| 2013-12-31 | $14.85 Million | -16.71% |
| 2012-12-31 | $17.83 Million | +13.22% |
| 2011-12-31 | $15.75 Million | -- |